Drug Database
ME

metformin + sitagliptin (Januvia ER / Janumet ER / Janumet XR)

✓ Approved

Merck & Co. · DPP4 · 小分子

什么是 metformin + sitagliptin?

metformin + sitagliptin 是一种小分子,由Merck & Co.研发。该药已获批,用于治疗相关适应症,给药途径:Oral (PO)。

药物档案

商品名Januvia ER, Janumet ER, Janumet XR
公司Merck & Co.
药物类别小分子
分子靶点DPP4
给药途径Oral (PO)
状态Approved

作用机制

分子靶点

metformin + sitagliptin 作用于 1 个分子靶点:

DPP4dipeptidyl peptidase 4 (CD26, DPPIV)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

metformin + sitagliptin 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersType 2 diabetes mellitus✓ Approved

相关研究文献

PubMedAmerican journal of physiology. Cell physiology2026-11-17

Effects of Anti-Diabetic Drugs on Satellite Cell Function: A Mini Review.

Skiles Chad M CM, Miranda Edwin R ER, Funai Katsuhiko K, Drummond Micah J MJ

Metformin, glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) and sodium glucose cotransport 2 inhibitors (SGLT2i) are the most frequently prescribed medications for the treatment of diabetes. While the efficacy of these anti-diabetic drugs is clear, the underlying mechanisms of how they improve metabolism and produce other seemingly beneficial off-target effects are not clear. Several tissues including skeletal muscle have been implicated in the on-target and off-target actions of these drugs. Satellite cells are muscle stem cells that are important for skeletal muscle adaptation to stimuli such as exercise. In this mini-review, we present the emerging evidence exploring whether Metformin, GLP-1RA, SGLT2i modulate satellite cell function and if this is a relevant therapeutic target.

PMID 43043123
阅读全文 →
PubMedAnimal models and experimental medicine2026-11-17

Metformin preconditioning potentiates the remyelinating effects of adipose-derived mesenchymal stem cells associated with decorin upregulation in a cuprizone model of demyelination.

Taghizadeh Fatemeh F, Pasbakhsh Parichehr P, Alikarami Ameneh A, Noorzehi Golaleh G et al.

Multiple sclerosis (MS) is a demyelinating disease of the central nervous system (CNS). Changes in the microenvironment surrounding oligodendrocyte progenitor cells (OPCs), characterized by excessive production of extracellular matrix (ECM) components driven by elevated TGF-β and CTGF signaling, impair the remyelination capacity of these cells. Decorin (DCN), an endogenous inhibitor of the TGF-β/CTGF signaling axis, has emerged as a potential regulator of ECM homeostasis. To improve the therapeutic outcomes of stem cell-based strategies, adipose-derived mesenchymal stem cells (ADMSCs) were preconditioned with metformin (MET) before transplantation into a C57BL/6 mouse model of cuprizone-induced demyelination. Cell viability and the expression of CXCR4 and SDF-1α were evaluated to determine the migratory potential following MET preconditioning. Remyelination and oligodendroglial lineage dynamics were assessed using Luxol Fast Blue (LFB) staining and analysis of MBP and NG2 expression. ECM remodeling and mechanosensitive signaling were evaluated through the expression of DCN, TGF-β, CTGF, and Piezo 1. MET preconditioning was optimized at 1 mmol/L for 24 h based on MTT assay results and increased the migratory potential of ADMSCs, as indicated by upregulation of the CXCR4/SDF-1α axis. Histological analysis revealed enhanced remyelination, accompanied by increased MBP and reduced NG2 expression in treated groups. At the molecular level, transplantation of MET-preconditioned ADMSCs upregulated DCN while downregulating TGF-β, CTGF, and Piezo 1 expression. MET preconditioning enhances the therapeutic efficacy of ADMSCs through increasing migration and homing of these cells and consequently promotes remyelination in a cuprizone-induced demyelination model, potentially through DCN-mediated mechanisms.

PMID 43040568
阅读全文 →
PubMedArchives of physiology and biochemistry2026-11-17

Pharmacological targeting of ageing hallmarks: molecular mechanism and clinical translation.

Su Lin L, Li Hongyao H, Yan Xiuying X

Background: Ageing is a gradual biological process characterized by progressive physiological decline and increased susceptibility to age-related diseases. The hallmarks of ageing provide a mechanistic framework for understanding these changes and identifying potential therapeutic targets. Objective: This review summarizes the major hallmarks of ageing, their links to age-related diseases, and pharmacological strategies targeting these mechanisms. Methods: We provide a narrative synthesis of current mechanistic and clinical evidence on candidate gerotherapeutics. Results: Pharmacological interventions targeting nutrient sensing, cellular senescence, mitochondrial dysfunction, and other aging-related pathways include metformin, rapamycin, senotherapeutics, and NAD+ precursors. These agents show potential to improve healthspan and reduce disease burden, although human evidence remains heterogeneous. Conclusion: Targeting the hallmarks of ageing represents a promising therapeutic strategy, but further well-designed clinical studies are needed to establish efficacy, safety, and clinically meaningful benefits.

PMID 43042699
阅读全文 →
PubMedDiabetes, obesity & metabolism2026-11-17

Real-World Initiation of Resmetirom and Recorded Incretin Exposure in the United States.

Papadimopoulos Ilias I, Gohar Najam N, Kokkorakis Michail M, Anagnostakis Filippos F

Resmetirom and semaglutide 2.4 mg are approved for metabolic dysfunction-associated steatohepatitis but have not been tested together. We examined recorded incretin exposure among resmetirom initiators and the frequency and correlates of co-initiation. This new-user cohort study used TriNetX US Collaborative Network health records of patients first prescribed resmetirom from 14 March 2024 to 16 July 2026. Among patients without incretin prescriptions in the prior 5 years, those with an incretin prescription 0-30 days after resmetirom (co-initiators) were compared with non-co-initiators using standardized mean differences (SMDs) and Mantel-Haenszel analysis stratified by overweight/obesity and Type 2 diabetes. Of 6837 initiators, 76.6% had overweight/obesity (code or body mass index [BMI] ≥ 30 kg/m2), 44.0% Type 2 diabetes and 16.8% a cirrhosis code. An incretin prescription was recorded in 37.2%, mostly before resmetirom (33.8%; excluded from the comparison). Of the remaining 4524, 231 (5.1%) were co-initiators. Coded overweight/obesity (49.4% vs. 49.0%; SMD: 0.01) and Type 2 diabetes (30.3% vs. 33.1%; SMD: 0.06) were similar; co-initiation was about 5% in every stratum (Mantel-Haenszel odds ratios: overweight/obesity 1.08 [95% CI: 0.80-1.46]; diabetes 1.00 [0.75-1.34]). Co-initiators had higher mean BMI (35.3 vs. 33.0 kg/m2; SMD: 0.33) and were more often prescribed metformin (27.7% vs. 19.0%; SMD: 0.21). Because more than one-third of resmetirom initiators had a recorded incretin prescription, mostly before initiation, trials of combined treatment are needed. Co-initiation was uncommon and not clearly associated with overweight/obesity or Type 2 diabetes, despite higher BMI in co-initiators.

PMID 43039875
阅读全文 →
PubMedF1000Research2026-11-17

Effectiveness of an Educational Intervention in the Integral Care of Patients with Diabetes Mellitus.

Goicochea-Rios Evelyn E, Otiniano Nélida Milly NM

To evaluate the effectiveness of an educational intervention in the integral care of patients with diabetes mellitus. A pre-experimental study was carried out with 103 patients with diabetes mellitus treated at Essalud, La Libertad, during the second semester of 2024. Pre and post educational intervention information was collected about knowledge of the disease, complications, physical activity and diet, adherence to treatment and family support, number of medical and nursing controls per quarter, glycemia values, HbA1c and compliance with treatment after informed consent. The educational intervention included theoretical aspects of diabetes mellitus, self-care, physical activity, nutrition and family support in 2-hour workshops, once a week, with a total of 4 sessions per participant. Predominantly female, mean age 63.22 years, higher education, marital status married/cohabiting and main occupation employed/independent. 97.1% had type 2 diabetes mellitus, 38.8% reported disease duration < 5 years, 72.8% were treated with metformin and the main comorbidity was hypertension (58.3%). The educational intervention improved knowledge about diabetes mellitus (p < 0.001), achieved a significant change in eating habits (p = 0.022) and family support (p = 0.043), and homogenized the level of support among families (p = 0.025).58.3% of the participants were noncompliant with the prescribed treatment. Treatment adherence fell from 54.4% to 41.7 %, whilst non-adherence rose from 45.6 % to 58.3 %; however 76.8% of patients who initially complied with treatment continued to do so after the intervention. The effectiveness of the educational program on glycemic control was not evidenced. Regarding integral control, 83.5 % of the patients received quarterly medical care and 44.7 % received nursing care. The educational program was effective in improving knowledge about T2D, adherence to healthy eating and significantly improved the level of family support and compliance with treatment.

PMID 43041325
阅读全文 →
PubMedClinical and translational science2026-11-17

Nine-Year Trends in Treatment Patterns, Comorbidities, and Healthcare Utilization in Type 2 Diabetes in France: Insights From Integrated Health Data.

Le Goff Romane R, Gouverneur Amandine A, Collin Cédric C, Rabiega Pascaline P et al.

Type 2 diabetes (T2D) is a chronic condition with multimorbidity. Treatment strategies have evolved gradually over the past decades. We described longitudinal treatments, comorbidities, and healthcare resource utilization (HCRU) among adults with T2D in France between 2015 and 2023. The OREOT cohort included adults with T2D identified between 2015 and 2018 in IQVIA Electronic Medical Records and linked to the French National Health Data System. Patients were followed until 31 December 2023. Baseline characteristics, longitudinal clinical data, treatment patterns, incident comorbidities, and HCRU were assessed. Treatment trajectories were reconstructed using state sequence analysis. Among 236,305 patients, 57% were men, and the median age was 67 years. At baseline, 77% of patients had hypertension, 62% had dyslipidemia, and 57% had cardiovascular disease. Over a median follow-up of 8.7 years, body mass index and HbA1c remained stable, whereas renal markers worsened (mean eGFR -7 mL/min/1.73 m2). Incident comorbidities were frequent, particularly cancer (21%) and chronic kidney disease (11%). Metformin use declined (from 73% to 65%), while use of glucagon-like peptide-1 receptor agonists (from 5% to 18%), sodium-glucose cotransporter-2 inhibitors (from 0% to 17%), and insulin (from 16% to 22%) increased, alongside growing regimen complexity. Healthcare utilization was characterized by frequent primary care visits (median 49 GP visits), with limited endocrinology (21%) and nephrology (5%) involvement, and regular HbA1c monitoring, with a median of three tests per year. Overall, 20% of patients died during follow-up. Between 2015 and 2023, T2D management in France shifted toward newer and more complex therapies, while a high burden of comorbidities and progressive renal decline persisted, highlighting the need for coordinated care and long-term real-world evaluation of newer glucose-lowering therapies.

PMID 43042779
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多metformin + sitagliptin